Press Room

Press Release / Nov 09, 2001

Address by the CEO on the inauguration of Building 2A in Macau

Speech during the Chinese Banquet at the Hyatt Hotel

Speech during the Chinese Banquet at the Hyatt Hotel to celebrate the inauguration of Building 2A in Macau on the 9th November 2001
 

Dear Friends,

Today we had the visit of the Macau Chief executive to mark the opening of the new facilities. This was a major effort and an investment of over $14m, we are all very pleased, but let me tell you how it all started.

An email dated 5th October, read as follows:

This is to advise the results of the competition of ideas; the decision of the jury was made public at a celebratory dinner on the 2nd October 1998. This was held at the Grémio Literário Club in Lisbon, the prizes were presented by Noé Carreira, José Rato and Guy Villax - members of the jury (Ivan Villax and Carlos Costa, also members of the jury, were not present).

The results were:

  • Joint 1st Prize:
    • Alfred Nobel - Jorge Pastilha
    • Lavoisier - Alexandre Carvalho
       
  • Joint 3rd Prize:
    • Baeyer Team - Terry, Eddy, Leong, Eric, Boli
    • Pasteur - José Lisboa
       
  • The awarded prizes were:
    • for each of the first prizes: about MOP45.000 in cash and a trip to Macau to see the new plant.
    • for each of the third prizes: a trip to Macau to see the new plant for José Lisboa and a trip to Lisbon for each of the Baeyer team members to see chemical plants in Europe1.

The 4 documents will be copied and made available internally - you can get a copy at the Human Resources Department.

The Jury extends its thanks and congratulations to all participants; the ideas gathered during the competition were very valuable and are a great contribution to the design of new installations.

Back in 1998 Hovione had just started up B15, its new automated plant in Loures with a technically challenging new project, which would turn into Hovione’s biggest ever product. We had just passed an FDA inspection; we could have decided to become complacent and pleased with ourselves – we did not.

We felt that our plant design could be improved – we were looking for more flexibility, quicker change-over-time, better compliance by design – a plant that would give us better quality, better yields and better profits. So that summer we opened a competition for the best idea for a new API plant. The people at Hovione had another challenge.

Today, this opening, is exclusively a tribute to Hovione people and to their sense of engineering and creativity, their ability to design, plan and implement, to work as a multidisciplinary team in a multicultural environment and to manage a project that is designed in Portugal and made reality in Macau.

The achievement observed tough constraints:

  • Full compliance with the toughest standards (FDA, ICH, ISPE);
  • Strict concern for minimal expenditure.

Let me tell you about the project:

  • Building 2A: we doubled the plant’s manufacturing capacity by adding 40m3 of reactors and 2 finishing lines with centrifuges/driers and packing rooms (class 100.000). All equipment is modular (identically and fully equipped) and totally flexible with the ability of interconnection in all situations. Separate sets of vents and vacuum lines enable the running of two separate products simultaneously with impossibility of cross- contamination. All equipment is connected to a DCS automation system;
  • Buildings 7A and 4: we doubled all the utilities (mono-fluid system for heating and cooling, solvent storage, etc.);
  • Building 11: we doubled the office space, and maintenance workshops;
  • Building 9: we renovated the old fire-cracker factory stone house and turned into our canteen and social area, this is set in a Chinese garden set in the middle of large, century old, banyan trees.

Budgets and timelines:

  • We have invested MOP120m investment (US$15m), overall we were 20% over budget;
  • From License application to start-up 24 months elapsed.

Lessons:

  • Improve our planning and project management skills;
  • Allow more time to plan, design and review design critically – this might increase slightly project time, but it will allow us to be in budget (better purchasing and better planning), do a better job right-first-time and have less pressure and stress;
  • Allow for more resources in the planning, controlling and project information function.

And to give glory, where glory is due, I must tell you that this project was the first one to be totally delegated to a project team of young in-house professionals. Noé Carreira, our Chief Engineer for 20 years was the project sponsor, and had an oversight role – otherwise the project team had “carte blanche” to design and implement what their training and career experience at Hovione told them was best: suited to our clients’ products, suited to difficult chemistries, flexible, compliant, engineered for quick-change-over and capable of earning profits while keeping our prices totally competitive, and our ability to being “always available” for the customer. I do mean “carte blanche”, both in terms of design and how the funds were spent.

My control over this project consisted on: signoff of the project baseline requirements and of the initial budget, and three visits to Macau. Somehow I am amazed at the ambition and the high standards the Project Team set for the “ideal plant”, the high level of investment it decided upon, the degree of sophistication in the automation, the ventilation, the CIP and product containment systems – the extensive use of hastelloy and stainless steel – and yet I authorized it and I trust the best judgment of the team; and I am sure this is the ideal plant. Over the coming 2 years we shall confirm this, and use your knowledge and experience to build more plants.

The stubbornness of the project team is to be commended! It may have led to some spurts of fury on my part, however on reflection no project manager could have achieved this exploit without the firmest belief in what he/she was doing the right thing.

I can imagine there have been some difficult moments, great pressures and too much constant stress. Yet I know that being involved in such a project is a terrific feeling, and the achievement of a job well done is worth everything. I know, I was here 15 years ago when we built the first phase of this plant.

Thank you for your efforts, and congratulations for your achievements – you can all be proud of yourselves and of your work.

Guy Villax
Chief Executive
Macau, 9th November 2001

 

 

1 As part of their European factories tour the Baeyer Team was kindly welcomed in Germany by Bayer, who organized visits in Kiel, Wuppertahl, Monheim and Leverkusen. The Baeyer team was made up of 5 plant operators (Eric Ng would seem to have had an undeclared leadership role… Eric today heads Safety and Warehouse services).

Also in the Press Room

See All

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet.   The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026.  As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities.    Read the full article at DCATvci.org  

Press Clipping

Supplier News: Thermo Fisher, Lonza, SK pharmteco, Hovione & More

Oct 30, 2025

Today marks the start of CPhI Frankfurt, a huge trade show in Germany focused on the supply of pharmaceutical ingredients and other services to the drug industry. C&EN editor in chief Nick Perkins, life sciences editor Laura Howes, and reporter Aayushi Pratap are all there to meet drug outsourcing executives and take the pulse of the sector. In advance of CPhI, Cambrex and Wilmington PharmaTech both just announced big investments in US plants that make active pharmaceutical ingredients. And the Portuguese pharmaceutical services firm Hovione says it has completed a $100 million investment in New Jersey (story below). (...) Hovione invests in spray-drying in New Jersey The pharmaceutical services firm Hovione says it has spent $100 million to expand its operation in East Windsor, New Jersey. The facility spray-dries drug ingredients to create amorphous solid dispersions, which improve solubility and bioavailability. The Portuguese company says the new spray dryers will begin operating in the second quarter of 2026. The New Jersey facility opened in 2002, making Hovione one of the longest-established European pharmaceutical services firms in the US, CEO Jean-Luc Herbeaux says in a press release. Hovione says it has purchased land adjacent to the East Windsor site on which it can add new facilities for services such as spray-drying and drug tableting. Hovione is also investing at its sites in Ireland and Portugal. —Michael McCoy   Read the full article at CEN.acs.org  

Press Clipping

Oct. 28 Business Watch: More plants closing in Europe, Novartis to pay $12 billion for biotech firm

Oct 28, 2025

Developing drugs with poor water solubility remains a major challenge for pharmaceutical manufacturers, because solubility impacts bioavailability and effective drug delivery. The vast majority of small molecule drug candidates have low water solubility. For more than two decades, the most successful particle engineering technology to improve drug solubility and bioavailability has been spray drying with an amorphous solid dispersion (ASD) platform. Spray drying improves the solubility of oral drugs, inhalable particles, and excipients, and increases the stability of heat-sensitive drug products. Hovione, recognized globally for its industry-leading spray drying capabilities, has recently completed a $100 million investment cycle to enhance its operations in New Jersey. This initiative has successfully doubled Hovione’s spray-drying capacity in the US, strengthening its position in the industry. Hovione’s Expanded U.S. Site in East Windsor, NJ  The first phase of the expansion in East Windsor, NJ, delivers a new 31,000 square foot facility and houses two size-3 spray dryers (PSD-3). This additional capacity allows Hovione to meet increasing customer demand for ASD development and good manufacturing practice (GMP) commercial production. GMP operations are scheduled to commence in the second quarter of 2026.  Hovione has also acquired 15 acres of neighboring land, strategically positioning itself for future growth and evolving customer needs for U.S. manufacturing. The newly acquired greenfield site will provide future support for PSD-4–scale commercial production as well as continuous and batch tableting production. It will also be a hub for centralized logistics, enhanced quality control laboratories, and next-generation research and development facilities.  A Global CDMO with a Growing U.S. Footprint  Hovione has operated in New Jersey for more than two decades, establishing itself with a strong U.S. presence for the production of drug substances, intermediates, and finished drug products. A continued emphasis on an integrated service offering, including spray drying, supports delivering innovative medicines to patients more quickly.  The expansion of the East Windsor site addresses the rising demand for U.S. manufacturing and is an integral part of the company's ongoing global growth strategy, with facilities in Portugal, Ireland, and Macau. The company continues to bolster a cohesive network for drug development and commercial manufacturing unified by a corporate quality system and governance framework.  The integrated offering enhances development speed and eases technology transfers by unifying the team's technical skills, proprietary technologies, and digital platforms to efficiently produce drug substance to drug products at a single-site, through Hovione’s “one site, one partner” vision. Furthermore, Hovione’s strategic partnership model offers customers exclusive access to advanced technologies and resources while aiding in the optimization of their development programs and ensuring sustained value creation.  End-to-End Spray Drying and Particle Engineering: From Grams to Tons Hovione is a global leader in spray drying and particle engineering. Services include solubility enhancement and controlled-modified release via development and production of ASDs of both small and large molecules, supporting various modalities. ASD-HIPROS, Hovione’s proprietary spray drying screening platform, identifies optimal formulations that offer optimal performance and stability. By increasing production volume in the US, Hovione will meet customer demand for spray drying services:  Development services in the laboratory (1 g – 1 kg batches)  Pilot scale production (0.5 – 25 kg batches)  Small-scale production (5 – 200 kg batches)  Large-scale commercial manufacturing (50 – 400 kg batches) A Commitment to Sustainability  Hovione’s core values include a commitment to sustainability at all facilities. This commitment is reflected in a business strategy that focuses on improving the communities where the company operates. Hovione’s sustainability policy and strategy align with the UN Sustainable Development Goals and include adherence to science-based targets in line with the Paris Agreement to address climate change. Meeting these goals has required a dedication to process intensification and ensuring sustainability of manufacturing processes. This has been possible through strategic planning and commitments from senior management to ensure sustainability is addressed throughout the drug development life cycle.  Partner with a Technology-Leading CDMO for U.S. Manufacturing   As demand for poorly water-soluble drug formulations continues to rise in the U.S., expanding spray drying throughput is essential to meet the need for innovative therapeutics. With proven leadership in spray drying to manufacture ASDs, Hovione is able to support pharmaceutical companies by solving their solubility challenges efficiently and reliably.  Partnering with a CDMO that combines global leadership, advanced technologies, and the necessary manufacturing capacity in the U.S., drug developers can expedite time to market, ensure quality, and deliver innovative medicines to patients faster.  If your company is seeking access to the latest spray-drying capabilities, expanded U.S. manufacturing capacity, and an accelerated path to regulatory filing and commercialization, contact our team today.     

News

Hovione is Expanding Spray Drying Capacity for U.S. Drug Manufacturing

Oct 27, 2025